Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-
Clinical Trials
Related News

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

First Posted Date
2005-06-03
Last Posted Date
2021-10-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
178
Registration Number
NCT00112502
Locations
🇺🇸

CCOP - Atlanta Regional, Atlanta, Georgia, United States

🇺🇸

CCOP - Central Illinois, Decatur, Illinois, United States

🇺🇸

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 9 locations

Celecoxib Treatment for Lung Cancer

Phase 1
Withdrawn
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Drug: Celecoxib
First Posted Date
2005-04-15
Last Posted Date
2014-10-29
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00108186
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, West LA, West Los Angeles, California, United States

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
Lung Cancer
Interventions
Drug: celecoxib
First Posted Date
2005-03-04
Last Posted Date
2015-10-02
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
7
Registration Number
NCT00104767
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

First Posted Date
2005-01-10
Last Posted Date
2013-07-11
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00101335
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase 2
Terminated
Conditions
Breast Cancer
First Posted Date
2005-01-10
Last Posted Date
2011-06-08
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Registration Number
NCT00101062
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

First Posted Date
2004-12-09
Last Posted Date
2016-12-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
23
Registration Number
NCT00099047
Locations
🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer

First Posted Date
2004-10-08
Last Posted Date
2015-10-08
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT00093678

S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Other: placebo
Drug: celecoxib
First Posted Date
2004-08-05
Last Posted Date
2018-08-10
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
8
Registration Number
NCT00088972
Locations
🇺🇸

Ben Taub General Hospital, Houston, Texas, United States

🇺🇸

Methodist Hospital, Houston, Texas, United States

🇺🇸

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States

and more 6 locations

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

First Posted Date
2004-08-05
Last Posted Date
2014-10-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
45
Registration Number
NCT00088959
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

Phase 3
Terminated
Conditions
Colorectal Cancer
Interventions
Other: placebo
Drug: Celecoxib
First Posted Date
2004-07-12
Last Posted Date
2013-01-07
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
18
Registration Number
NCT00087256
Locations
🇺🇸

Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy